Ultragenyx Pharmaceutical RARE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $93M-9.7% | $145.79M+25.8% | $111.94M+14.4% | $120.41M+5.9% | $103M+24.7% | |
| Non Cash Royalty | $20M+5.3% | $37.58M+11.9% | $24.91M+8.1% | $30.32M+15.3% | $19M+5.2% | |
| Royalty | $47M-2.1% | $105.6M+13.3% | $64.94M+4.3% | $85.68M+17.0% | $48M+3.6% | |
| Royalty Percentage On Net Sales by Geography | ||||||
| European Union And Switzerland And Turkey | 10%0.0pp | —— | —— | —— | 10%0.0pp | |
| Royalty Revenue For Sales In North American Territiory | 30%— | —— | —— | —— | —— | |
| Revenue by Geography | ||||||
| Asia Pacific | $4M+33.3% | $5.36M+47.3% | $5.15M+123% | $4.2M+37.7% | $3M— | |
| EMEA | $31M+34.8% | $30.39M+18.5% | $27.88M+25.5% | $26.4M+63.4% | $23M+44.0% | |
| Latin America | $42M-23.6% | $38.78M+106% | $43.36M+14.0% | $32.97M-15.3% | $55M+56.3% | |
| North America | $59M+1.7% | $132.75M+13.9% | $83.54M+8.6% | $102.93M+15.8% | $58M+0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
